Sqaurex
  • Home
  • About Us
    • About Us
    • Management
    • Contact US
  • Clinical Trials
    • Clinical Trials
    • Clinical Trials Sign Up
  • Investors
  • More
    • Home
    • About Us
      • About Us
      • Management
      • Contact US
    • Clinical Trials
      • Clinical Trials
      • Clinical Trials Sign Up
    • Investors
Sqaurex
  • Home
  • About Us
    • About Us
    • Management
    • Contact US
  • Clinical Trials
    • Clinical Trials
    • Clinical Trials Sign Up
  • Investors

Press Releases

Squarex Announces Successful End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset

Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results from its Phase 2 clinical study on humans with its novel asset SQX770 for prevention of cold sores also known as herpes labialis or oral herpes, an illness caused by herpes simplex virus, usually type 1 (HSV-1). 


SQX770 is a unique, first in class topical immunomodulator. SQX770 is the only product shown to reduce the number of cold sore events or flareups as well as their severity.  

Find out more

Preventing Oral Herpes Outbreaks

April 2, 2021

Developing Options for Not Just Treating, But Preventing,

Outbreaks of Herpes Labialis (Cold Sores or Oral Herpes)

Find out more

Press Release

April 20, 2021

Squarex, LLC, Announces the Hiring 

of Joseph Cunningham as CFO

Find out more
  • Contact US

Copyright © 2023 Squarex - All Rights Reserved.

Powered by GoDaddy Website Builder

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept